Observational multicentre prospective study to assess changes in cognitive function in patients treated with PCSK9i. Study protocol

Observational multicentre prospective study to assess changes in cognitive function in patients treated with PCSK9i. Study protocol

<p><strong>Objective:</strong> PCSK9 inhibitors have been shown to reduce LDLc by up to about 60% and 85% when used with high doses of statins and ezetimibe (2019 ESC/EAS Guidelines). These therapies may lead to very low levels of LDLc and have been associated with possible cogn...

Full description

Bibliographic Details
Main Authors: José Seijas-Amigo, Diego Rodríguez-Penas, Ana Estany-Gestal, Pedro Suárez-Artime, María Santamaría-Cadavid, José Ramón González-Juanatey
Format: Article
Language:English
Published: Grupo Aula Médica 2021-05-01
Series:Farmacia Hospitalaria
Subjects:
alirocumab
evolocumab
pcsk9 inhibitors
cholesterol
cognition
lipid-lowering therapies
Online Access:http://www.aulamedica.es/fh/pdf/11569.pdf

Internet

http://www.aulamedica.es/fh/pdf/11569.pdf

Similar Items